Core Viewpoint - The announcement highlights that the inhalation solution of human interferon α 1b, developed by the company's wholly-owned subsidiary, has been included in the list of breakthrough therapies by the National Medical Products Administration [1] Group 1: Product Development - The human interferon α 1b inhalation solution is a significant breakthrough in the antiviral field for the company [1] - This medication is specifically designed for children and is administered via nebulization, allowing the active ingredient to reach the site of infection more quickly [1] - Compared to injectable forms, this inhalation solution offers higher acceptance and safety for pediatric patients, as they do not have to endure the pain of injections [1] Group 2: Indications and Applications - The indication for the human interferon α 1b inhalation solution is for pediatric respiratory syncytial virus (RSV) lower respiratory tract infections, including pneumonia and bronchiolitis [1]

Core Viewpoint - The announcement highlights that the inhalation solution of human interferon α1b, developed by the wholly-owned subsidiary of the company, has been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration [1] Group 1: Product Development - The inhalation solution is intended for the treatment of pediatric respiratory syncytial virus lower respiratory tract infections, including pneumonia and bronchiolitis [1] - As of the date of the announcement, the human interferon α1b inhalation solution is in the Phase III clinical trial stage [1] Group 2: Company Actions - The company will actively promote the research and development project and fulfill its information disclosure obligations in a timely manner [1]

Group 1 - The core point of the news is that Kexing Pharmaceutical's stock price has dropped by 5.03%, currently trading at 38.50 yuan per share, with a total market capitalization of 7.748 billion yuan [1] - Kexing Biopharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of recombinant protein drugs and micro-ecological preparations, with 97.38% of its revenue coming from pharmaceutical products [1] - The company was established on August 22, 1997, and went public on December 14, 2020 [1] Group 2 - Huatai Baoxing Fund holds a significant position in Kexing Pharmaceutical, with its Huatai Baoxing Kexing A fund (009124) owning 21,000 shares, representing 1.59% of the fund's net value [2] - The fund has experienced a floating loss of approximately 42,800 yuan today [2] - The fund was established on May 11, 2020, and has a current scale of 20.8067 million yuan, with a year-to-date return of 7.86% [2] Group 3 - The fund managers of Huatai Baoxing Kexing A are Zhou Yongmei and Chen Qiwei, with Zhou having a tenure of 7 years and 232 days and Chen having a tenure of 2 years and 98 days [3] - Zhou's fund has a total asset scale of 8.897 billion yuan, with the best return during her tenure being 43.64% [3] - Chen's fund has a total asset scale of 24.594 billion yuan, with the best return during his tenure being 18.95% [3]

Market Overview - On September 22, the biopharmaceutical sector experienced a slight decline of 0.15%, with Kanglaosheng leading the drop [1] - The Shanghai Composite Index closed at 3828.58, up 0.22%, while the Shenzhen Component Index closed at 13157.97, up 0.67% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aipumai (688293) with a closing price of 58.70, up 9.90% on a trading volume of 47,100 shares and a turnover of 267 million yuan [1] - Baipusais (301080) closed at 61.75, up 5.05% with a trading volume of 38,300 shares and a turnover of 231 million yuan [1] - Muli Pharmaceutical (603087) closed at 73.60, up 3.76% with a trading volume of 182,000 shares and a turnover of 134.2 million yuan [1] - Conversely, the following stocks saw significant declines: - Kanglaosheng (833575) closed at 14.71, down 6.90% with a trading volume of 90,400 shares and a turnover of 137 million yuan [2] - Kexing Pharmaceutical (688136) closed at 40.54, down 3.20% with a trading volume of 47,600 shares and a turnover of 194 million yuan [2] - Changchun High-tech (000661) closed at 122.10, down 2.49% with a trading volume of 102,800 shares and a turnover of 1.265 billion yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 473 million yuan from institutional investors, while retail investors contributed a net inflow of 418 million yuan [2] - The following stocks had notable capital flows: - Ganli Pharmaceutical (603087) had a net inflow of 58.16 million yuan from institutional investors [3] - Rongchang Biotechnology (688331) saw a net inflow of 43.73 million yuan from institutional investors [3] - ZhiXiangJinTai (688443) had a net inflow of 6.53 million yuan from retail investors [3]

Core Viewpoint - Recently, Sinovac Biotech (688136.SH) disclosed the results of a shareholder inquiry transfer report and a notice regarding changes in the equity of shareholders holding more than 5% of shares, indicating significant share reductions by its major shareholder, Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. [1] Summary by Relevant Sections Shareholder Equity Changes - Shenzhen Keyi Pharmaceutical reduced its holdings by a total of 18,314,717 shares, which represents 9.62% of the company's total equity [2][3] - The share reductions occurred through various methods, including a block trade and inquiry transfers, with specific dates and amounts detailed [2] Financial Impact - The average share price during the reduction period was 46.60 RMB, leading to a total cash-out amount of approximately 853,465,812.2 RMB [1] Ownership Structure Post-Reduction - After the reductions, Shenzhen Keyi Pharmaceutical holds 109,688,630 shares, accounting for 54.50% of the total equity, while its associated party, Deng Xueqin, holds 1,764,125 shares, or 0.88% [2][3] - The combined holdings of Shenzhen Keyi Pharmaceutical and Deng Xueqin amount to 111,452,755 shares, representing 55.38% of the total equity [3] Control and Governance - The transfer of shares will not result in a change of the controlling shareholder or the actual controller of the company, and it is not expected to significantly impact the company's governance structure or ongoing operations [3]

Group 1 - The core viewpoint of the news is that the weight loss drug sector experienced a significant decline in stock prices after an initial rise, indicating volatility in this market segment [1] - Specifically, Borui Pharmaceutical saw a drop of over 10% after previously rising more than 9% [1] - Other companies in the sector, such as Zhongsheng Pharmaceutical, fell over 7%, while Tianenkang, Kexing Pharmaceutical, Baihua Pharmaceutical, and Jinkaishengke also experienced declines [1]

Core Viewpoint - The recent share transfer by Kexing Pharmaceutical indicates a strategic move towards preparing for a potential IPO in Hong Kong, with significant capital operations involving both share reduction by the controlling shareholder and bond issuance by the company [1][2][3] Group 1: Share Transfer Details - Kexing Pharmaceutical's controlling shareholder, Koyi Medicine, transferred 10.0628 million unrestricted shares at a price of 30.88 yuan per share, totaling approximately 311 million yuan, which represents 5% of the total share capital [1] - The transfer price reflects a nearly 30% discount compared to the average price over the previous 20 trading days and a significant drop from the 36.7 yuan per share price in early August [1] - The effective subscription multiple was only 1.01 times, indicating weak demand from institutional investors [1] Group 2: Financial Performance and Future Plans - Koyi Medicine has raised a total of 754 million yuan through various share reduction methods over the past three months [1] - Kexing Pharmaceutical plans to issue up to 800 million yuan in technology innovation bonds, creating a dual funding flow strategy of shareholder reduction and corporate bond issuance [1][2] - The company reported a net profit of 80.3445 million yuan in the first half of the year, a year-on-year increase of 576.45%, with cash flow from operating activities turning positive [2] Group 3: Market Implications and Investor Sentiment - The high discount and rapid pace of share reduction suggest a pressing need for cash by the controlling shareholder and a cautious outlook on short-term stock price movements [2][3] - Koyi Medicine's shareholding has decreased from 66.01% to 54.5%, still above the 25% public holding requirement for Hong Kong listings, indicating that further share distribution will be necessary for a successful IPO [2] - The introduction of 35 institutional investors through the share transfers enhances the diversity and stability of the company's shareholder structure, potentially boosting confidence among international investors for the upcoming IPO [2]

Market Overview - The biopharmaceutical sector experienced a decline of 1.9% on September 19, with Kanghong Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3820.09, down 0.3%, while the Shenzhen Component Index closed at 13070.86, down 0.04% [1] Stock Performance - Notable gainers included: - Aopumai (688293) with a closing price of 53.41, up 1.71% on a trading volume of 34,700 shares and a turnover of 189 million yuan [1] - Kexing Pharmaceutical (688136) closed at 41.88, up 1.70% with a trading volume of 45,300 shares and a turnover of 189 million yuan [1] - Significant decliners included: - Kanghong Pharmaceutical (002773) which fell 6.09% to a closing price of 37.00, with a trading volume of 94,100 shares and a turnover of 355 million yuan [2] - Changchun High-tech (000661) decreased by 3.91% to 125.22, with a turnover of 1.674 billion yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 999.7 million yuan from institutional investors, while retail investors had a net inflow of 914 million yuan [2] - The table of capital flow indicates that: - Changchun High-tech had a net inflow of 67.986 million yuan from institutional investors [3] - Kanghua Biological (300841) experienced a net inflow of 11.825 million yuan from institutional investors [3]

证券代码：688136 证券简称：科兴制药 公告编号：2025-077 深圳科益医药控股有限公司（以下简称"科益医药"或"转让方"）及其一致行 动人邓学勤保证向科兴生物制药股份有限公司（以下简称"公司"或"科兴制药"）提 供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示: 55.38%，累计权益变动比例触及 5%的整数倍。 一、 转让方情况 (一)转让方基本情况 截至 2025 年 9 月 12 日转让方所持公司股份的数量、比例情况如下： 科兴生物制药股份有限公司 股东询价转让结果报告书暨持股 5%以上股东权益变动 触及 5%整数倍的提示性公告 (二)转让方一致行动关系及具体情况说明 本次询价转让的转让方科益医药系公司实际控制人、董事长邓学勤控制的企业， 科益医药与邓学勤属于一致行动关系。 序号 股东姓名 持股数量 （股） 持股比 例 拟转让数 量（股） 实际转让数量 （股） 实际转让 数量占总 股本比例 转让后持 股比例 1 科益医药 119,751,430 59.50% 10,062,800 10,062,80 ...

科兴生物制药股份有限公司 简式权益变动报告书 上市公司名称：科兴生物制药股份有限公司 股票上市地点：上海证券交易所 股票简称：科兴制药 股票代码：688136 信息披露义务人一：深圳科益医药控股有限公司 通讯地址：深圳市南山区粤海街道科兴科学园 D1 栋 42 层 信息披露义务人二：邓学勤 通讯地址：深圳市南山区粤海街道科兴科学园 D1 栋 42 层 股份变动性质：股份减少 签署日期：2025 年 9 月 19 日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"） 《上市公司收购管理办法》（以下简称"《收购办法》"）《证券期货法律适用意见 第 19 号——<上市公司收购管理办法>第十三条、第十四条的适用意见》《公开 发行证券公司信息披露内容与格式准则第 15 号—权益变动报告书》（以下简称 "准则 15 号"）及相关的法律、法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《证券法》《收购办法》《证券期货法律适用意见第 19 号——<上 市公司收购管理办法>第十 ...